200 related articles for article (PubMed ID: 27101910)
1. Bioresorption and Vessel Wall Integration of a Fully Bioresorbable Polymeric Everolimus-Eluting Scaffold: Optical Coherence Tomography, Intravascular Ultrasound, and Histological Study in a Porcine Model With 4-Year Follow-Up.
Nakatani S; Ishibashi Y; Sotomi Y; Perkins L; Eggermont J; Grundeken MJ; Dijkstra J; Rapoza R; Virmani R; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Apr; 9(8):838-851. PubMed ID: 27101910
[TBL] [Abstract][Full Text] [Related]
2. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
3. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
4. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies.
Gogas BD; Radu M; Onuma Y; Perkins L; Powers JC; Gomez-Lara J; Farooq V; Garcia-Garcia HM; Diletti R; Rapoza R; Virmani R; Serruys PW
Int J Cardiovasc Imaging; 2012 Mar; 28(3):499-511. PubMed ID: 21503708
[TBL] [Abstract][Full Text] [Related]
5. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
[TBL] [Abstract][Full Text] [Related]
6. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
7. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
[TBL] [Abstract][Full Text] [Related]
8. Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model.
Campos CM; Ishibashi Y; Eggermont J; Nakatani S; Cho YK; Dijkstra J; Reiber JH; Sheehy A; Lane J; Kamberi M; Rapoza R; Perkins L; Garcia-Garcia HM; Onuma Y; Serruys PW
Int J Cardiovasc Imaging; 2015 Mar; 31(3):471-82. PubMed ID: 25627777
[TBL] [Abstract][Full Text] [Related]
9. Imaging Comparison of a Bioresorbable Vascular Scaffold by High-Frequency Intravascular Ultrasound and Optical Coherence Tomography.
Shan P; Motivala A; Moses J; Maehara A; Mintz GS; Ali ZA
JACC Cardiovasc Interv; 2015 Sep; 8(11):e187-e188. PubMed ID: 26404210
[No Abstract] [Full Text] [Related]
10. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
[TBL] [Abstract][Full Text] [Related]
11. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
[TBL] [Abstract][Full Text] [Related]
12. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes.
Kochman J; Tomaniak M; Pietrasik A; Kołtowski Ł; Rdzanek A; Huczek Z; Mazurek T; Jąkała J; Ząbek A; Legutko J; Kochman W; Filipiak KJ
Cardiol J; 2015; 22(3):315-22. PubMed ID: 25428734
[TBL] [Abstract][Full Text] [Related]
13. Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial.
Brugaletta S; Gomez-Lara J; Bruining N; Radu MD; van Geuns RJ; Thuesen L; McClean D; Koolen J; Windecker S; Whitbourn R; Oberhauser J; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
EuroIntervention; 2012 Jul; 8(3):352-8. PubMed ID: 22130182
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
15. Novel ultrahigh molecular weight amorphous PLLA bioresorbable coronary scaffold upsized up to 0.8 mm beyond nominal diameter: An OCT and histopathology study in porcine coronary artery model.
Gasior P; Cheng Y; Estrada EA; Jenn McGregor ; Ramzipoor K; Lee C; Conditt GB; Rousselle SD; Granada JF; Kaluza GL
Catheter Cardiovasc Interv; 2018 Feb; 91(3):378-386. PubMed ID: 28471065
[TBL] [Abstract][Full Text] [Related]
16. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
[TBL] [Abstract][Full Text] [Related]
17. Comparative Biomechanical Behavior and Healing Profile of a Novel Thinned Wall Ultrahigh Molecular Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
Cheng Y; Gasior P; Xia JG; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
Circ Cardiovasc Interv; 2017 Jul; 10(7):. PubMed ID: 28701488
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Serruys PW; Onuma Y; Garcia-Garcia HM; Muramatsu T; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Ormiston JA
EuroIntervention; 2014 Mar; 9(11):1271-84. PubMed ID: 24291783
[TBL] [Abstract][Full Text] [Related]
19. Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
Gutiérrez-Chico JL; Gijsen F; Regar E; Wentzel J; de Bruyne B; Thuesen L; Ormiston J; McClean DR; Windecker S; Chevalier B; Dudek D; Whitbourn R; Brugaletta S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2012 Apr; 5(4):428-35. PubMed ID: 22516401
[TBL] [Abstract][Full Text] [Related]
20. Difference in haemodynamic microenvironment in vessels scaffolded with Absorb BVS and Mirage BRMS: insights from a preclinical endothelial shear stress study.
Tenekecioglu E; Torii R; Bourantas C; Sotomi Y; Cavalcante R; Zeng Y; Collet C; Crake T; Suwannasom P; Onuma Y; Serruys PW
EuroIntervention; 2017 Dec; 13(11):1327-1335. PubMed ID: 28590249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
